---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-018334"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-26T00:03:19.762315+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BBOT to merge with Helix II SPAC in $450M deal; public listing expected Q3 2025

## Summary
- Total proceeds ~$450M from Helix trust (~$196M) and $260M PIPE led by Cormorant, including Deerfield, Novo Holdings, Wellington.
- Combined company to be named BridgeBio Oncology Therapeutics (BBOT), trading on Nasdaq under ticker BBOT.
- Pro forma equity value ~$949M at $10.36/share assuming no redemptions; BBOT shareholders roll 100% equity.
- Lead programs: BBO-8520 (KRAS G12C Phase 1), BBO-10203 (RAS-PI3Kα Phase 1), BBO-11818 (pan-KRAS Phase 1 starting H1 2025).
- Transaction approved by both boards; expected close Q3 2025, subject to stockholder approvals and conditions.

## SEC filing metadata
- accession: 0001213900-25-018334
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025018334/0001213900-25-018334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025018334/ea0232555-8k425_helix2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-018334
- JSON: https://secwatch.observer/filing/0001213900-25-018334.json
- Plain text: https://secwatch.observer/filing/0001213900-25-018334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.